Abstract
The inherent limitations of conventional cancer therapies have stimulated the growth of cancer nanomedicine. This is primarily attributable to its unique features for drug delivery, diagnosis and imaging, synthetic vaccine development and miniature medical devices, supplemented with the inherent therapeutic property of some nanomaterials. Nanotherapies that integrate some of these features are already in use and others have great potential in clinical development, with definitive results in near future. In order to develop smart cancer nanomedicine, it is very essential to bridge the gap between Bio-Nanoscience and Cancer Nanomedicine with a better understanding about the molecular basis of cancer. The development of smart cancer nanomedicine can be accelerated by patient stratification, rational drug selection, combination therapy, synergism with immunotherapeutics. The nanoplatforms that exhibit a significant increase in progression free survival are most desirable.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
